Variation in the reference range limits of thyroid function tests and association with the prevalence of levothyroxine treatment.

Eur J Endocrinol

Department of Diabetes and Endocrinology, Northumbria Healthcare NHS Foundation Trust, North Tyneside, United Kingdom.

Published: February 2023

Many individuals with marginally abnormal thyroid function test (TFT) results may be treated and it is unknown if the limits of the thyrotropin (TSH) and free thyroxine (FT4) reference intervals reported alongside the laboratory results are associated with the prevalence of levothyroxine treatment. We obtained information regarding reported TFT reference intervals from UK National Health Service (NHS) laboratories and evaluated its relationship with the prevalence of levothyroxine treatment for corresponding health areas for 2014. The upper limit of serum TSH was significantly, linearly, independently, and negatively associated with prevalent levothyroxine treatment: -0.54% (95% CI, -0.68% to -0.40%). The lower limit of serum FT4 was significantly and independently associated with the prevalence of levothyroxine treatment in a non-linear (J-shaped) manner with an increase being noted from a FT4 level of ≈9.5 pmol/L onwards. We conclude that minor changes in the reference range limits for serum TSH and FT4 are associated with levothyroxine treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejendo/lvad016DOI Listing

Publication Analysis

Top Keywords

levothyroxine treatment
24
prevalence levothyroxine
16
reference range
8
range limits
8
thyroid function
8
reference intervals
8
associated prevalence
8
limit serum
8
serum tsh
8
levothyroxine
6

Similar Publications

"Jiedutongluo Tiaoying Formula" (JDTLTYF) TCM prescriptions can effectively treat hyperthyroidism and effectively improve the condition of patients. The main active ingredients of JDTLTYF were collected from the TCMSP database and the target was predicted. Genes related to hyperthyroidism were identified using DisGeNET, GeneCards and OMIM databases.

View Article and Find Full Text PDF

Newborn screening and the screening laboratory: past, present and future.

Eur Thyroid J

January 2025

A Heijboer, Department of Laboratory Medicine, Endocrine Laboratory, Amsterdam, 1105AZ, Netherlands.

Thyroid hormone (TH) is essential for brain development in utero and during the first two to three years of life. The negative effects of TH deficiency on brain development are irreversible. Early detection of TH deficiency in neonates (congenital hypothyroidism (CH) through newborn screening (NBS)) allows for early treatment, thereby preventing brain damage.

View Article and Find Full Text PDF

Objectives: Neudesin is a newly discovered protein mainly secreted from adipose tissue and the brain. It plays a role as a neurotrophic factor in the brain and a negative regulator of energy expenditure. Neurodevelopmental delay and cognitive dysfunction are common features in cases with congenital hypothyroidism (CH) without treatment.

View Article and Find Full Text PDF

Objectives: Moebius syndrome (MS) is a rare congenital non-progressive rhombencephalic disorder mostly characterised by abducens and facial nerve palsy, but with a multifaceted clinical presentation. Isolated or multiple pituitary hormone deficiencies in the setting of MS have been occasionally reported, but the simultaneous involvement of three or more hypothalamic-pituitary axes has never been described. We hereby report the case of a girl with MS that showed a co-occurrence of GH-, TSH- and ACTH-deficiency.

View Article and Find Full Text PDF

Treatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy.

Endocr Metab Immune Disord Drug Targets

January 2025

Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: Combination therapy with levothyroxine (L-T4) and slow-release T3 (SRT3) in the treatment of hypothyroidism results in a normal triiodothyronine/thyroxine (T3/T4) ratio above that of L-T4 monotherapy. No clinical study has been reported with SRT3 monotherapy for hypothyroidism.

Methods: This study was conducted in two parts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!